Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What CAGR And Valuation Are Anticipated For The Intravenous Iron Drugs Market?

The market size of intravenous iron drugs has seen a significant increase in the past few years. It is projected to rise from $3.44 billion in 2024 to $3.81 billion in 2025, with a compound annual growth rate (CAGR) of 10.6%. Factors such as the growing occurrence of iron deficiency anemia, an upsurge in chronic diseases, an increase in healthcare expenditure, an aging population, and increased incidents of target diseases have driven growth during the historic period.

Expectations for the intravenous iron drugs market size suggest a swift expansion within the coming years. By 2029, the valuation could reach $5.73 billion, with a compound annual growth rate (CAGR) of 10.8%. Numerous factors contribute to this anticipated growth in the forecast period, testament to government initiatives, developments in research for IV iron drugs, rising demand for intravenous iron medications, an increase in the scope for research and development activities, along with enhancements in administration and formulation. Several trends are set to shape the forecast period, such as the introduction of superior intravenous iron therapies, progress in drug development, the leaning towards more user-friendly IV iron therapies, tactful collaborations, partnerships and takeovers, as well as novel drug delivery system innovations.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23430&type=smp

What Are The Primary Factors Supporting The Intravenous Iron Drugs Market Expansion?

The rise in occurrences of chronic kidney disease (CKD) is projected to accelerate the expansion of the intravenous iron drugs market. CKD is characterized by the slow deterioration of kidney function over time, which results in the kidneys’ incapacity to effectively eliminate waste and surplus fluids from the blood. The escalating prevalence of CKD can be attributed to increased incidences of diabetes and hypertension, which over time inflict damage on the kidneys. Intravenous iron drugs are beneficial for patients with CKD as they restore iron reserves, amend anemia, and boost hemoglobin concentrations, enhancing oxygen transport and minimizing the requirement for erythropoiesis-stimulating agents. For example, data reported by the Australian Institute of Health and Welfare, a government agency based in Australia, in June 2024 showed that death rates due to CKD surged by 4.2% in 2021 and by 6.2% in 2022. CKD accounted for roughly 22,000 deaths in Australia in 2022, corresponding to 11% of all deaths. Consequently, the rising prevalence of CKD is fuelling the expansion of the intravenous iron drugs market.

Which Segmentation Categories Are Highlighted In The Intravenous Iron Drugs Market Analysis?

The intravenous iron drugs market covered in this report is segmented –

1) By Product Type: Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Other Product Types

2) By Indication: Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Diseases

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Iron Dextran: Low Molecular Weight Iron Dextran, High Molecular Weight Iron Dextran

2) By Iron Sucrose: Standard Iron Sucrose Injection, Iron Sucrose Complex

3) By Ferric Carboxymaltose: Single-Dose Ferric Carboxymaltose, Multiple-Dose Ferric Carboxymaltose

4) By Other Product Types: Ferumoxytol, Ferric Derisomaltose, Sodium Ferric Gluconate

Which Market Trends Are Expected To Define The Future Of The Intravenous Iron Drugs Market?

The key players in the intravenous iron drugs market are concentrating their efforts on the development of breakthrough therapies, such as IV iron replacement therapy. This innovative medical treatment, which allows iron to be delivered directly into the bloodstream through an intravenous infusion, aims to enhance efficacy, safety, and overall patient results, particularly for those with iron deficiency and anemia who are unable to effectively absorb or tolerate oral iron supplements. An example of such a development came in June 2023 when Daiichi Sankyo Company Limited, a renowned pharmaceutical firm based in Japan specializing in creative drug development and healthcare solutions, received approval from the U.S. Food and Drug Administration for Injectafer (ferric carboxymaltose injection). The medication, known for its ability to quickly restore iron levels in patients unresponsive to or incapable of tolerating oral iron supplements, has been approved for use in treating iron deficiency among adult heart failure patients classified as New York Heart Association class II/III, with the goal of enhancing their exercise capacity.

Which Players Are Shaping The Competitive Landscape Of The Intravenous Iron Drugs Market?

Major companies operating in the intravenous iron drugs market are AbbVie Inc., Sanofi S.A., Amgen Inc., Fresenius SE & Co. KGaA, Teva Pharmaceutical Industries Ltd., CSL Limited, Sandoz Group AG., Daiichi Sankyo Company Ltd., Sun Pharmaceutical Industries Ltd., Galenica Ltd., Dr.Reddy’s Laboratories, Hikma Pharmaceuticals plc, Zydus Lifesciences Limited, Biocon Limited, Kissei Pharmaceutical Co. Ltd., American Regent Inc., Akebia Therapeutics Inc., Rockwell Medical Inc., Pharmacosmos A/S, Shield Therapeutics plc, Mitsubishi Tanabe Pharma Corporation

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/intravenous-iron-drugs-global-market-report

Which Regional Markets Are Emerging As Key Hubs For The Intravenous Iron Drugs Market?

North America was the largest region in the intravenous iron drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous iron drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=23430&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model